Fresenius Medical Care Corp’s 2026 Q2 Earnings Call: Growth Forecasts and TDAPA Impact Contradict Prior Guidance

<<>>

Date of Call: Aug 4, 2026

Business Commentary:

Strong Financial Performance and Strategic Initiatives:

• Fresenius Medical Care reported a significant operating income growth of 23% in Q2 2026, aligning with their planned phasing for the year, and achieved 7% organic revenue growth in the Care Delivery segment.
• The growth was driven by solid organic revenue development, margin expansion, and the continued execution of their FME25+ transformation program, which delivered EUR 67 million in sustainable savings.

U.S. Market Challenges and Organizational Response:

• The U.S. same-market treatment growth declined by 0.9% in Q2 2026, attributed to an operational miss in business development and referral capture.
• The company addressed this with organizational changes and new measures, aiming to restore referral rates, though the impact is expected to persist, with growth around the Q2 level anticipated for the full year.

Value-Based Care and Innovation Momentum:

• The Value-Based Care segment reported a 9% increase in revenue, driven by contracting growth and improved member months, with a significant reduction in losses compared to the previous year.
• This performance was supported by the company's vertically integrated model leading to better patient outcomes, alongside strategic initiatives like the introduction of TherapyWise and kinexus, enhancing digital transformation and home dialysis capabilities.

High-Volume HDF Rollout and Positive Outcomes:

• Fresenius Medical Care made progress with the 5008X machine rollout, converting 10% of their machine base by late July, with positive patient and clinical feedback.
• The rollout is accelerating as planned, supported by real-world evidence initiatives like BEACON-US, indicating early positive experiences with high-volume HDF treatments.

Inflationary Pressures and Cost Management:

• The company faced challenges from elevated raw material and logistics costs due to the Middle East conflict, impacting the Care Enablement segment.
• These pressures were managed within their guidance range, supported by the ongoing execution of the FME25+ program to drive sustainable savings and offset increasing costs.

Contradiction Point 1

U.S. Same-Market Treatment Growth Outlook

Expectations for 2026 growth shift from flat to negative.

Jonathan (Barclays) - Jonathan (Barclays)

2026Q2: Due to compounding effects, 2026 U.S. same-market treatment growth is expected to be around the Q2 level (~ -0.9%). - Helen Giza(CEO)

Can you detail the deceleration in U.S. same-market treatment growth from Q1 to Q2, particularly on referrals, and whether it's fair to assume this trend worsens throughout 2026? - Hassan (Barclays)

2026Q1: The full-year expectation remains for flat same-market treatment growth. - Helen Giza(CEO)

Contradiction Point 2

Timing & Scale of the TDAPA Financial Impact

Guidance for 2026 TDAPA contribution changes significantly.

Veronika (Citi) - Veronika (Citi)

2026Q2: The total TDAPA contribution is now expected to be a negative €50M year-over-year for 2026. - Martin Fischer(CFO)

With strong H1 performance, is the new full-year guidance (€50M headwind) for TDAPA phosphate binder conservative? - Hassan (Barclays)

2026Q1: The company expects a significant headwind from TDAPA in the second half of 2026, leading to the guidance for positive operating income growth in H1 and negative growth in H2. - Martin Fischer(CFO)

Contradiction Point 3

U.S. Same-Market Treatment Growth Recovery Timeline

Contradictory statements on when patient inflow improvements will materialize.

Jonathan (Barclays) - Jonathan (Barclays)

2026Q2: Improvements are anticipated to take hold more in 2027. - Helen Giza(CEO)

Can you detail the deceleration in U.S. same-market treatment growth from Q1 to Q2, particularly on referrals, outline steps to improve patient inflow, and provide expectations for growth trends through 2026 and the 2027 exit rate? - James (Jefferies)

2025Q4: The path to returning to 2%+ same market treatment growth is based on... The 2025 figure also had one fewer treatment day due to holiday timing. The path to returning to 2%+ same market treatment growth is based on these initiatives and the HDF rollout. - Helen Gieser(CEO)

Contradiction Point 4

Outlook for ACA Headwind in 2027

Contradiction on the availability and nature of guidance for the 2027 ACA impact.

Ayesha (Morgan Stanley) - Ayesha (Morgan Stanley)

2026Q2: It is too early to size the 2027 ACA headwind. The company expects to incorporate its effects into the 2027 business growth number... - Helen Giza(CEO)

Can you quantify the ACA headwind for Q2 and full-year 2026, and share any early thoughts for 2027? - Veronica (Citi)

2025Q4: The impact is ~€50 million in 2026. The company will update its assessment as more information becomes available. - Helen Gieser(CEO)

Contradiction Point 5

Outlook for U.S. Same-Market Treatment Growth

Contradiction on the expected performance and improvement timeline for U.S. treatment growth.

Jonathan (Barclays) - Jonathan (Barclays)

2026Q2: 2026 U.S. same-market treatment growth is expected to be around the Q2 level (~ -0.9%). Improvements are anticipated to take hold more in 2027. - Helen Giza(CEO)

Can you detail the deceleration in U.S. same-market treatment growth from Q1 to Q2, particularly on referrals, and whether it's fair to assume this trend worsens through 2026, along with the expected exit rate for 2027? - Hassan Al-Wakeel (Barclays Bank PLC)

2025Q3: Confidence in returning to 2%+ same-market treatment growth remains once mortality normalizes, which is expected to happen. The rollout of High-Volume Hemodialysis (HDF) in 2026 is also anticipated to help... - Helen Giza(CEO)

<<>>